Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Warmth of Medicine: The Irreplaceability of Doctors in the Era of Artificial Intelligence.

Journal of medical Internet research·2026
Same author

10-year cardiovascular disease risk and its contributing factors in primary hyperparathyroidism.

Endocrine·2026
Same author

Association of baseline osteocalcin and femoral neck bone mineral density in healthy women with future risk of fractures, cardiovascular disease, diabetes and death.

Frontiers in endocrinology·2025
Same author

Remarkable Inhibition Efficacy of a Compound Plant Essential Oil Disinfectant Against Bacteria, Viruses, and Mycoplasmas.

Veterinary sciences·2025
Same author

Gut Microbiota-Decanoic Acid-Interleukin-17A Axis Orchestrates Hyperglycemia-Induced Osteoporosis in Male Mice.

Diabetes·2025
Same author

Approach to the Patient With Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1.

The Journal of clinical endocrinology and metabolism·2025

Related Experiment Videos

Parathyroid Carcinoma: From Molecular Pathogenesis to Multidisciplinary Management.

Jia-Xi Song1,2, Yu-Ying Yang1,2, Jin-Xin Zhou3

  • 1Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

The Journal of Clinical Endocrinology and Metabolism
|July 4, 2026
PubMed
Summary
This summary is machine-generated.

Parathyroid carcinoma (PC) is a rare cancer. Early diagnosis and surgical removal are key, with ongoing research into targeted therapies for advanced cases.

Keywords:
hypercalcemiaparathyroid carcinomaparathyroidectomyprimary hyperparathyroidism

Related Experiment Videos

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Parathyroid carcinoma (PC) is a rare endocrine malignancy, representing less than 1% of primary hyperparathyroidism cases.
  • Understanding its molecular drivers is crucial for improving diagnosis and treatment.
  • Current knowledge on PC pathogenesis, diagnosis, imaging, management, and prognosis is synthesized in this review.

Purpose of the Study:

  • To review the current understanding of parathyroid carcinoma.
  • To highlight key aspects of its molecular pathogenesis, diagnosis, imaging, management, and prognosis.
  • To emphasize the importance of multidisciplinary care for optimizing patient outcomes.

Main Methods:

  • Literature review summarizing current knowledge on parathyroid carcinoma.
  • Analysis of molecular pathogenesis, including genetic mutations and pathway alterations.
  • Evaluation of diagnostic criteria, imaging modalities, and treatment strategies.
  • Review of prognostic factors and follow-up recommendations.

Main Results:

  • PC is primarily driven by CDC73 mutations, affecting parafibromin expression, with involvement of PI3K/AKT/mTOR and Wnt pathways.
  • Diagnosis is challenging, requiring clinical suspicion based on severe hypercalcemia, elevated PTH, neck mass, or nerve palsy.
  • Imaging like ultrasound, 99mTc-sestamibi, 4D-CT, and PET/CT aids localization and metastasis detection.
  • En bloc resection with thyroid lobectomy is standard; medical therapies manage calcium, while radiotherapy/chemotherapy have limited roles.
  • Recurrence rates are high (23-65%), necessitating lifelong follow-up.
  • Prognostic factors include surgical approach, remission, Ki-67, parafibromin, and mTOR status.

Conclusions:

  • Parathyroid carcinoma diagnosis and management require a high index of suspicion and specialized multidisciplinary care.
  • While surgery is the primary treatment, targeted therapies show potential for advanced disease.
  • Effective management hinges on accurate diagnosis, surgical expertise, and vigilant long-term follow-up.